Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients
- Conditions
- Food Allergy
- Interventions
- Drug: Glucopyranosyl Lipid A (GLA)Drug: Placebo for GLADrug: Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)Drug: Placebo for SLIT PE
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 27
- Registration Number
- NCT03463135
- Locations
- 🇺🇸
Investigational Site Number 8400004, Little Rock, Arkansas, United States
🇺🇸Investigational Site Number 8400019, Mission Viejo, California, United States
🇺🇸Investigational Site Number 8400008, San Diego, California, United States
Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus
- Conditions
- Microvascular Coronary Artery Disease
- Interventions
- First Posted Date
- 2018-03-12
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 54
- Registration Number
- NCT03462017
- Locations
- 🇩🇪
Investigational Site Number 2760001, Neuss, Germany
🇩🇪Investigational Site Number 2760002, Mainz, Germany
Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2018-03-12
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 41
- Registration Number
- NCT03462069
- Locations
- 🇩🇪
Investigational Site Number 2760001, Berlin, Germany
Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 84
- Registration Number
- NCT03449758
- Locations
- 🇫🇷
Investigational Site Number 250014, Caen, France
🇫🇷Investigational Site Number 250006, Besancon, France
🇫🇷Investigational Site Number 250016, Bordeaux, France
Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease
- Conditions
- Non-alcoholic SteatohepatitisType 2 Diabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Sanofi
- Registration Number
- NCT03437720
Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 45
- Registration Number
- NCT03436498
- Locations
- 🇺🇸
Investigational Site Number 8400001, Little Rock, Arkansas, United States
🇺🇸Investigational Site Number 8400002, Denver, Colorado, United States
🇺🇸Investigational Site Number 8400003, West Des Moines, Iowa, United States
Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 241
- Registration Number
- NCT03434119
- Locations
- 🇺🇸
Investigational Site Number 8400069, Anaheim, California, United States
🇺🇸Investigational Site Number 8400043, Columbia, South Carolina, United States
🇺🇸Investigational Site Number 8400072, Montgomery, Alabama, United States
A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT03414736
- Locations
- 🇺🇸
Investigational Site Number 8400003, Knoxville, Tennessee, United States
🇺🇸Investigational Site Number 8400002, Saint Paul, Minnesota, United States
🇺🇸Investigational Site Number 8400001, Austin, Texas, United States
A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril
- Conditions
- Healthy SubjectsDiabetes Mellitus
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT03414723
- Locations
- 🇩🇪
Investigational Site Number 2760001, Berlin, Germany
Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
- Conditions
- Hypercholesterolaemia
- Interventions
- Device: Current auto-injector device (AI)Device: New auto-injector device (SYDNEY)
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 69
- Registration Number
- NCT03415178
- Locations
- 🇺🇸
Investigational Site Number 8400022, Summerville, South Carolina, United States
🇺🇸Investigational Site Number 8400017, Jacksonville, Florida, United States
🇺🇸Investigational Site Number 8400013, Ponte Vedra, Florida, United States